After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer therapy ...
Capital Market on MSN
Glenmark gains after launching first-ever nebulized triple therapy for COPD
The therapies combine three proven medicines-Glycopyrronium, Formoterol, and Budesonide-to reduce airway obstruction, control ...
SNS Insider Reports Steady Growth of the U.S. Asthma and COPD Drugs Market from USD 8.56 Billion in 2025E to USD 12.68 Billion by 2033, Supported by Awareness Programs, Expanding Biologic Usage, and ...
Drugmaker AstraZenecasaid it intends to cap out-of-pocket prices of four medicines used to treat asthma and chronic obstructive pulmonary disease (COPD) to $35 per month for many patients. Starting ...
The global monoclonal antibody for asthma and COPD market size was valued at USD 34.02 billion in 2025 and is predicted to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback